Researchers develop molecule, move step closer to treating common cold

Image
IANS London
Last Updated : May 16 2018 | 4:15 PM IST

Moving closer to finding a cure for common cold, researchers have developed a molecule that may prevent the virus from attacking human cells.

Researchers from the Imperial College in London have developed the molecule that targets protein called N-myristoyltransferase(NMT) which cold viruses need to build a protein 'shell', or capsid, which protects the virus genome.

According to the study, the new molecule attacks this protein instead of the virus which may, in turn, stop the formation of the resistant viruses.

The molecule also combats other related viruses that cause polio and foot and mouth disease.

"Common cold is an inconvenience for most of us, but can cause serious complications in people with conditions like asthma and chronic obstructive pulmonary disease. A drug like this could be extremely beneficial, if given early in infection. We are working on making a version that could be inhaled, so that it gets to the lungs quickly," said lead researcher Ed Tate, Professor at the Department of Chemistry at the Imperial College.

The results showed that the new molecule completely blocked several strains of the virus without affecting human cells. However, further study is needed to make sure that it is not toxic.

"The way the drug works means that we would need to be sure it was used against cold virus, and not similar conditions with different causes, to minimise the chance of toxic side effects," Tate added.

Presently, the remedies include treating symptoms instead of the virus as it is almost impossible to be get immunity against cold-causing viruses and hundred of variants which develop resistance quickly.

--IANS

sh/rt/tsb/vm

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 16 2018 | 4:08 PM IST

Next Story